Description:
The enzyme, aldo-keto reductase family 1-member C (AKR1C3), is a well-known contributor to prostate cancer, acute myeloid leukemia, and chemotherapeutic resistance. However, current inhibition research has only identified compounds with an insufficient degree of selectivity for AKR1C3 over its other isoforms.
This invention has established a method of synthesizing an AKR1C3 inhibitor with 1800 fold selectivity over related isoforms and permits more effective cancer treatment. The research has identified known AKR1C3 inhibitors and altered them to increase selectivity. Unlike previous AKR1C3 research, the high selectivity of this invention affords a significant likelihood of approval for clinical testing.
Reference Number: D-1318
Market Applications:
- Oncology
- Pharmaceuticals
- Cancer treatment research
- Organic synthesis research
Features, Benefits & Advantages:
- Inhibiting AKR1C3 prevents the development of chemotherapeutic resistant cancers
- Selectivity for AKR1C3 only maintains other healthy and normal hormonal levels
- Increased survival rates for prostate and breast cancer and AML patients
- Decreased lengths of hospital stays
- Reduced treatment costs
Intellectual Property:
A U.S. Provisional Patent application, Serial 62/458,267 was filed on 2/13/17.
A PCT Application was filed PCT/US2018/0017986
Development Stage:
This invention has been reduced to practice and is currently at the proof of concept stage in development.
Researchers:
Paul Trippier, Ph. D., Assistant Professor, Department of Pharmaceutical Science, Texas Tech University Health Science Center, Amarillo, Texas
Keywords: AKR1C3 inhibitor, Leukemia, Breast Cancer, Prostate Cancer, AKR1C3 Selectivity